Sarepta Therapeutics Announces At-the-Market Equity Offering Facility
Wall Street Journal
… for general corporate purposes, including for manufacturing scale up for eteplirsen, the planned confirmatory Phase III clinical study of eteplirsen and early development activities related to follow-on Duchenne muscular dystrophy drugs and other …
READ AT
http://online.wsj.com/article/PR-CO-20130703-908304.html
